课题基金 / 基金详情

Hepatitis B virus immunity in Indigenous and "at risk" children who received hepatitis B vaccination in infancy

Hepatitis B virus immunity in Indigenous and "at risk" children who received hepatitis B vaccination in infancy
在婴儿期接受乙型肝炎疫苗接种的土著儿童和“高危”儿童的乙型肝炎病毒免疫力
批准号:
nhmrc : 396700
负责人:
A/Pr Nicholas Wood
金额:
$14.25万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2006
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2006-01-01 至 2007-12-31

项目摘要

项目成果

A/Pr Nicholas Wood的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Hepatitis B virus (HBV) is transmitted by blood exposure or sexual contact and infection can result in chronic liver disease and liver cancer. Since 2000 Hepatitis B virus immunisation has been recommended for all infants in Australia with the first dose given at birth. However, prior to routine universal immunisation, a selective immunisation strategy was used in Australia from 1986. This targeted infants considered at high risk of HBV infection because of high prevalence in their population of origin, (including Aboriginal- Torres Strait Islanders) and infants whose mother was a HBV carrier. These children, among the first to be vaccinated, are now adolescents. There have been no long-term follow-up studies in Australia, and limited studies elsewhere, to assess the extent of breakthrough infection and persistence of immunity to Hepatitis B after vaccine at birth. As onset of sexual activity is associated with an increased exposure to hepatitis B infection, booster doses may be needed, especially in high-risk individuals. This study includes 2 high risk groups - young indigenous adults in the Northern Territory and young adults born to HBV carrier mothers in central Sydney. It will measure the number of children who have been infected with HBV or are chronic carriers, compared to pre immunisation data, and also the persisting level of immunity in children who were vaccinated against HBV as an infant. Children whose blood test indicates that they have low immunity will be given a booster dose of HBV vaccine and their immune response measured. A rise in hepatitis B antibody following booster vaccination indicates that you have immunological memory and is currently considered to show protection from natural hepatitis B infection. If clinically significant HBV infections are found to be rare and immunologic memory can be demonstrated, this would provide good evidence to support the argument that booster vaccine doses are not required in the Australian context.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VACCINE SAFETY RESEARCH in understudied and at risk groups: critical knowledge to inform practice and policy.
  • 批准号:
    nhmrc : 1142873
  • 项目类别:
    Career Development Fellowships
  • 资助金额:
    $19.34万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Nicholas Wood
  • 依托单位:
Immunisation safety and adverse events: Improving our understanding of causes and management
  • 批准号:
    nhmrc : 1063629
  • 项目类别:
    Career Development Fellowships
  • 资助金额:
    $19.69万
  • 财政年份:
    2014
  • 负责人:
    A/Pr Nicholas Wood
  • 依托单位:
Febrile seizures following vaccination in children: How common are they and what is the long term clinical outcome?
  • 批准号:
    nhmrc : 1049557
  • 项目类别:
    Project Grants
  • 资助金额:
    $46.26万
  • 财政年份:
    2013
  • 负责人:
    A/Pr Nicholas Wood
  • 依托单位:
Evolution of pertussis epidemics and effect of genotypes on infection outcomes and immunisation
  • 批准号:
    nhmrc : 1011942
  • 项目类别:
    Project Grants
  • 资助金额:
    $43.86万
  • 财政年份:
    2011
  • 负责人:
    A/Pr Nicholas Wood
  • 依托单位:
国内基金
海外基金
基于CRISPR/Cas9文库筛选蜱传病毒Tamdy virus感染相关宿主因子及其作用机制的研究
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    周宏
  • 依托单位:
DNA糖苷酶OGG1调节PARP1介导的EB病毒潜伏蛋白表达的机制研究
基于寨卡病毒NS1和NS5的海洋微生物中抗病毒化合物的发现
  • 批准号:
    81973204
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2019
  • 负责人:
    宋福行
  • 依托单位:
苹果茎沟病毒(Apple stem grooving virus, ASGV)CP基因介导的RNAi 转基因对ASGV侵染和脱毒的影响研究
  • 批准号:
    31801709
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2018
  • 负责人:
    冯超红
  • 依托单位: